A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia

Clinical Psychopharmacology and Neuroscience

Volumn 10, Issue 2, 2012, Pages 61-70

  Nurjono, Milawaty ^a   Lee, Jimmy ^a   Chong, Siow Ann ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

Biomarkers; Brain derived neurotrophic factor; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; CYSTEINE; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GLUTAMATE DECARBOXYLASE 67; HALOPERIDOL; HYDROCORTISONE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METHIONINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RISPERIDONE; SEROTONIN; THREONINE; TUMOR NECROSIS FACTOR ALPHA; VALINE; VESICULAR GLUTAMATE TRANSPORTER 1;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ASTROCYTE; B LYMPHOCYTE; BRAIN REGION; CELL SURVIVAL; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CYTOKINE PRODUCTION; CYTOLOGY; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG SAFETY; ENDOPLASMIC RETICULUM; ESTROGEN BLOOD LEVEL; EVIDENCE BASED DENTISTRY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HIPPOCAMPUS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LONG TERM POTENTIATION; LONGITUDINAL STUDY; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MONOCYTE; MORTALITY; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NEUROPATHOLOGY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; PSYCHOSIS; PSYCHOSOCIAL REHABILITATION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; T LYMPHOCYTE; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 84865804807     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2012.10.2.61     Document Type: Review

References (122)

1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008;102:1-18.
2. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 2009;110:1-23.
3. Wong AH, Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003;27:269-306. (Pubitemid 36681541)
4. van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-645.
5. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res 2008;106:89-107.
6. Buckley PF, Pillai A, Howell KR. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 2011;24:122-127.
7. Balaratnasingam S, Janca A. Brain Derived Neurotrophic Factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther 2012;134:116-124.
8. Favalli G, Li J, Belmonte-de-Abreu P, Wong AH, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res 2012;46:1-11.
9. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982;1:549-553.
10. Lu B, Martinowich K. Cell biology of BDNF and its relevance to schizophrenia. Novartis Found Symp 2008;289:119-129.
11. Binder DK, Helen LH, Anthony WN. Brain-derived neurotrophic factor. Encyclopedia of hormones. New York: Academic press:2003.p.209-214.
12. Thoenen H. The changing scene of neurotrophic factors. Trends Neurosci 1991;14:165-170.
13. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 2007;85:525-535.
14. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H. BDNF function and intracellular signaling in neurons. Histol Histopathol 2010;25:237-258.
15. Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008;33:73-83. (Pubitemid 350191318)
16. Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 2008;89:312-323. (Pubitemid 351318269)
17. Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 2005;15:319-329. (Pubitemid 40487736)
18. Lipsky RH, Marini AM. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 2007;1122:130-143. (Pubitemid 350249544)
19. Nanko S, Kunugi H, Hirasawa H, Kato N, Nabika T, Kobayashi S. Brain-derived neurotrophic factor gene and schizophrenia: polymorphism screening and association analysis. Schizophr Res 2003;62:281-283. (Pubitemid 36773938)
20. Szekeres G, Juhász A, Rimanóczy A, Kéri S, Janka Z. The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr Res 2003;65:15-18. (Pubitemid 37410398)
21. Jönsson EG, Edman-Ahlbom B, Sillén A, Gunnar A, Kulle B, Frigessi A, et al. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:924-933.
22. Xu MQ, St Clair D, Ott J, Feng GY, He L. Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis. Schizophr Res 2007;91:6-13.
23. Kawashima K, Ikeda M, Kishi T, Kitajima T, Yamanouchi Y, Kinoshita Y, et al. BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. Schizophr Res 2009;112:72-79.
24. Yi Z, Zhang C, Wu Z, Hong W, Li Z, Fang Y, et al. Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population. Brain Res 2011;1417:146-150.
25. Zakharyan R, Boyajyan A, Arakelyan A, Gevorgyan A, Mrazek F, Petrek M. Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population. Hum Immunol 2011;72:746-748.
26. Zintzaras E. Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis. Psychiatr Genet 2007;17:69-75. (Pubitemid 46586677)
27. Watanabe Y, Nunokawa A, Kaneko N, Someya T. Meta-analysis of case-control association studies between the C270T polymorphism of the brain-derived neurotrophic factor gene and schizophrenia. Schizophr Res 2007;95:250-252. (Pubitemid 47313632)
28. Hajek T, Kopecek M, Höschl C. Reduced hippocampal volumes in healthy carriers of brain-derived neurotrophic factor Val66Met polymorphism: meta-analysis. World J Biol Psychiatry 2012;13:178-187.
29. Takahashi T, Suzuki M, Tsunoda M, Kawamura Y, Takahashi N, Tsuneki H, et al. Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons. Neurosci Lett 2008;435:34-39.
30. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-269. (Pubitemid 36144114)
31. Hong CJ, Liou YJ, Tsai SJ. Effects of BDNF polymorphisms on brain function and behavior in health and disease. Brain Res Bull 2011;86:287-297.
32. Pivac N, Nikolac M, Nedic G, Mustapic M, Borovecki F, Hajnsek S, et al. Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:356-362.
33. Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN, et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008;33:2200-2205. (Pubitemid 351992089)
34. Spalletta G, Morris DW, Angelucci F, Rubino IA, Spoletini I, Bria P, et al. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur Psychiatry 2010;25:311-313.
35. Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011;36:195-203.
36. Vasic N, Connemann BJ, Wolf RC, Tumani H, Brettschneider J. Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand? Eur Arch Psychiatry Clin Neurosci 2011. [Epub ahead of print]
37. Issa G, Wilson C, Terry AV Jr, Pillai A. An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis 2010;39:327-333.
38. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998;37:1553-1561. (Pubitemid 28550429)
39. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011;14:347-353.
40. Chen D, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009;207:375-380.
41. Rizos EN, Papathanasiou M, Michalopoulou PG, Mazioti A, Douzenis A, Kastania A, et al. Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophr Res 2011;129:201-204.
42. Pirildar S, Gönül AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:709-713. (Pubitemid 38987396)
43. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009;66:549-553.
44. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Xu Q, et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res 2007;41:997-1004. (Pubitemid 47304448)
45. Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1508-1512.
46. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005;382:27-32.
47. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011;16:960-972.
48. Carlino D, Leone E, Di Cola F, Baj G, Marin R, Dinelli G, et al. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res 2011;45:273-279.
49. Angelucci F, Mathé AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000;60:783-794.
50. Chlan-Fourney J, Ashe P, Nylen K, Juorio AV, Li XM. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002;954:11-20. (Pubitemid 35223437)
51. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002;57:247-258. (Pubitemid 35240027)
52. Pedrini M, Chendo I, Grande I, Lobato MI, Belmonte-de-Abreu PS, Lersch C, et al. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett 2011;491:207-210.
53. Yang YQ, Sun S, Yu YQ, Li WJ, Zhang X, Xiu MH, et al. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neurosci Lett 2011;502:37-40.
54. Liou YJ, Liao DL, Chen JY, Wang YC, Lin CC, Bai YM, et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 2004;5:243-251.
55. Carlsson A, Hansson LO, Waters N, Carlsson ML. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 1997;61:75-94. (Pubitemid 27274014)
56. Sokoloff P, Guillin O, Diaz J, Carroll P, Griffon N. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders. Neurotox Res 2002;4:671-678. (Pubitemid 35390310)
57. Guillin O, Demily C, Thibaut F. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol 2007;78:377-395.
58. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, O'Dowd BF, et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A 2009;106:21377-21382.
59. Djalali S, Höltje M, Grosse G, Rothe T, Stroh T, Grosse J, et al. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J Neurochem 2005;92:616-627.
60. Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH, et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 1999;96:15239-15244. (Pubitemid 30019796)
61. Celada P, Siuciak JA, Tran TM, Altar CA, Tepper JM. Local infusion of brain-derived neurotrophic factor modifies the firing pattern of dorsal raphé serotonergic neurons. Brain Res 1996;712:293-298.
62. Lang UE, Hellweg R, Gallinat J. Association of BDNF serum concentrations with central serotonergic activity: evidence from auditory signal processing. Neuropsychopharmacology 2005;30:1148-1153. (Pubitemid 40720973)
63. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 1991;48:996-1001.
64. Arnold SE, Franz BR, Gur RC, Gur RE, Shapiro RM, Moberg PJ, et al. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry 1995;152:738-748.
65. Zaidel DW, Esiri MM, Harrison PJ. Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Am J Psychiatry 1997;154:812-818. (Pubitemid 27230104)
66. Blennow K, Davidsson P, Gottfries CG, Ekman R, Heilig M. Synaptic degeneration in thalamus in schizophrenia. Lancet 1996;348:692-693.
67. Ernfors P. Local and target-derived actions of neurotrophins during peripheral nervous system development. Cell Mol Life Sci 2001;58:1036-1044. (Pubitemid 32756514)
68. McAllister AK. Neurotrophins and neuronal differentiation in the central nervous system. Cell Mol Life Sci 2001;58:1054-1060. (Pubitemid 32756516)
69. Lu B, Chang JH. Regulation of neurogenesis by neurotrophins: implications in hippocampus-dependent memory. Neuron Glia Biol 2004;1:377-384.
70. Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N, et al. Stress and inflammation reduce brain- derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 2011;72:1677-1684.
71. Smith GN, Thornton AE, Lang DJ, Macewan GW, Ehmann TS, Kopala LC, et al. Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis. Schizophr Res 2012;134:253-259.
72. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188:510-518. (Pubitemid 43844097)
73. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011;68:128-137.
74. Woods BT. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry 1998;155:1661-1670. (Pubitemid 28547488)
75. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005;10:434-449. (Pubitemid 40646432)
76. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002;25:409-432. (Pubitemid 34748023)
77. Murakami S, Imbe H, Morikawa Y, Kubo C, Senba E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neurosci Res 2005;53:129-139. (Pubitemid 41219528)
78. Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry 2004;55:708-714. (Pubitemid 38376182)
79. Elzinga BM, Molendijk ML, Oude Voshaar RC, Bus BA, Prickaerts J, Spinhoven P, et al. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology (Berl) 2011;214:319-328.
80. Zhang XY, Liang J, Chen DC, Xiu MH, De Yang F, Kosten TA, et al. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl) 2012. [Epub ahead of print]
81. Rund BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 1998;24:425-435. (Pubitemid 28378227)
82. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26:119-136. (Pubitemid 30317696)
83. Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, Keogh JM, et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 2006;55:3366-3371. (Pubitemid 44923594)
84. Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Kanahara N, Hashimoto T, et al. Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1836-1840.
85. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4-14.
86. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010;119:101-109.
87. McCreadie RG; Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-539.
88. Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007;28:857-864. (Pubitemid 47351113)
89. Simons LA, Simons J, Friedlander Y, McCallum J. Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo study. Heart Lung Circ 2011;20:214-219.
90. de Simone G, Devereux RB, Chinali M, Roman MJ, Lee ET, Resnick HE, et al. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. Nutr Metab Cardiovasc Dis 2009;19:98-104.
91. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005;66:183-194.
92. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010;196:116-121.
93. Auquier P, Lançon C, Rouillon F, Lader M. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2007;16:1308-1312.
94. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000;19:1290-1300. (Pubitemid 30151025)
95. Lebrun B, Bariohay B, Moyse E, Jean A. Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. Auton Neurosci 2006;126-127:30-38. (Pubitemid 43833352)
96. Rosas-Vargas H, Martínez-Ezquerro JD, Bienvenu T. Brain-derived neurotrophic factor, food intake regulation, and obesity. Arch Med Res 2011;42:482-494.
97. Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM, et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS One 2010;5:e10099.
98. Chaldakov G. The metabotrophic NGF and BDNF: an emerging concept. Arch Ital Biol 2011;149:257-263.
99. Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res 2004;146:279-289. (Pubitemid 37541389)
100. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007;7:46.
101. Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, et al. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 2010;118:211-217.
102. Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev Neurother 2007;7:789-796. (Pubitemid 47037719)
103. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001;47:13-25. (Pubitemid 32121767)
104. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801-808. (Pubitemid 351410515)
105. Suvisaari J, Loo BM, Saarni SE, Haukka J, Perälä J, Saarni SI, et al. Inflammation in psychotic disorders: a population-based study. Psychiatry Res 2011;189:305-311.
106. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-671.
107. Altamura AC, Boin F, Maes M. HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 1999;10:1-4.
108. Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Müller N. T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res 2007;152:173-180. (Pubitemid 47212477)
109. Riedel M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Möller HJ, et al. Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 2007;41:3-7. (Pubitemid 44708207)
110. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001;15:319-339. (Pubitemid 34044519)
111. Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, et al. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 2006;78:3571-3576. (Pubitemid 43848947)
112. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009;63:257-265.
113. Braun A, Lommatzsch M, Mannsfeldt A, Neuhaus-Steinmetz U, Fischer A, Schnoy N, et al. Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 1999;21:537-546. (Pubitemid 129504276)
114. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999;189:865-870. (Pubitemid 29189691)
115. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003;53:292-304. (Pubitemid 36258633)
116. Gureje O, Bamidele RW. Gender and schizophrenia: association of age at onset with antecedent, clinical and outcome features. Aust N Z J Psychiatry 1998;32:415-423. (Pubitemid 28306365)
117. Castle D, Sham P, Murray R. Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr Res 1998;33:179-183. (Pubitemid 28446542)
118. Riecher-Rössler A, Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. In: Neill JC, Kulkarni J, editors. Biological basis of sex differences in psychopharmacology. Berlin-Heidelberg: Springer;2011. p.155-171.
119. Wong J, Rothmond DA, Webster MJ, Shannon Weickert C. Increases in Two Truncated TrkB Isoforms in the Prefrontal Cortex of People With Schizophrenia. Schizophr Bull 2011. [Epub ahead of print]
120. Sohrabji F, Lewis DK. Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front Neuroendocrinol 2006;27:404-414. (Pubitemid 44738016)
121. Solum DT, Handa RJ. Estrogen regulates the development of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus. J Neurosci 2002;22:2650-2659. (Pubitemid 37465814)
122. Gibbs RB. Treatment with estrogen and progesterone affects relative levels of brain-derived neurotrophic factor mRNA and protein in different regions of the adult rat brain. Brain Res 1999;844:20-27. (Pubitemid 29490948)